SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) provided preliminary unaudited Q4 and full‑year 2025 results, issued 2026 guidance, and announced an executive transition plan.
Q4 2025: revenue of at least $21 million (+~20% YoY) and >105,000 analyses (+16% YoY). FY 2025: revenue of ~ $77 million (+~18% YoY) and a company record >391,000 analyses. FY 2026 guidance: revenue $92–94 million (~20–22% growth) and adjusted EBITDA loss $29–32 million. Leadership changes: Ross Muken promoted to CEO effective July 1, 2026; co‑founder Jurgi Camblong to transition to Executive Chairman (subject to election in June 2026). Results are preliminary and unaudited; final results expected on the March 3, 2026 earnings call.
Positive
- FY 2025 revenue +18% to ~$77 million
- Q4 2025 revenue at least $21 million (+~20% YoY)
- Analyses performed record 391,000 in 2025
- FY 2026 revenue guidance $92–94 million (~20–22% growth)
- Leadership succession internal CEO promotion supports continuity
Negative
- FY 2026 adjusted EBITDA loss $29–32 million (ongoing cash burn)
- Preliminary unaudited results may materially change on final close
- Executive transition introduces implementation and governance risk
News Market Reaction
On the day this news was published, SOPH declined 2.65%, reflecting a moderate negative market reaction. Argus tracked a trough of -16.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $359M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SOPH gained 6.65% with strong volume while peers showed mixed performance: notably SLP rose 16.18%, but others like MNDR and LFMD declined. Momentum scanner only flagged LFMD, supporting a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | AI partnership | Positive | +4.2% | Strategic collaboration with MD Anderson on AI-driven precision oncology. |
| Nov 11 | Platform partnership | Positive | +6.2% | Integration of MSK assays with DNBSEQ-T1+ to scale oncology testing. |
| Nov 11 | AI integration deal | Positive | +6.2% | Co-marketing AI-powered assays on new high-throughput sequencing platform. |
| Nov 11 | Sequencing partnership | Positive | +6.2% | Partnership with Element Biosciences to link AVITI systems with SOPHiA DDM. |
| Nov 04 | Earnings update | Positive | -6.4% | Q3 2025 beat on growth and raised guidance but shares fell post-release. |
Stock has generally reacted positively to partnership/AI news, with one notable negative reaction to prior earnings despite raised guidance.
Over the past year, SOPH has combined steady revenue growth with expanding AI and sequencing partnerships. Collaborations with MD Anderson, Complete Genomics, and Element Biosciences all coincided with positive price reactions of around 4–6%. Earlier earnings in 2025 showed double-digit revenue growth and improving adjusted margins, though the Q3 2025 report saw a -6.4% move. Today’s preliminary 2025 results and 2026 guidance extend this growth narrative while adding a defined CEO succession plan.
Market Pulse Summary
This announcement combines preliminary Q4/FY 2025 results, 2026 guidance, and a detailed CEO succession plan. Revenue and analysis volumes continued to grow, and management outlined expectations for ~20–22% revenue growth next year alongside a reduced but still meaningful adjusted EBITDA loss. The transition to a new CEO in July 2026 follows years of internal leadership development. Investors may watch upcoming audited results, progress toward the 2026 loss targets, and execution under the evolving leadership team.
Key Terms
liquid biopsy medical
adjusted EBITDA financial
AI-generated analysis. Not financial advice.
The Company finishes 2025 with strong Q4 performance, expects 20
Fourth Quarter 2025 Preliminary Unaudited Financial Results
- Revenue of at least
$21 million 20% year-over-year - Performed over 105,000 analyses on SOPHiA DDM™ in the fourth quarter, representing
16% year-over-year growth
Full Year 2025 Preliminary Unaudited Financial Results
- Revenue of approximately
$77 million 18% year-over-year - Performed over 391,000 analyses on SOPHiA DDM™ in 2025, a new company record
"2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth," said Jurgi Camblong, Chief Executive Officer of SOPHiA GENETICS. "Our strong performance in 2025 positions us well for continued growth in 2026 and beyond. Growth catalysts for the year ahead include our best-in-class Liquid Biopsy application MSK-ACCESS® powered with SOPHiA DDM™, valuable opportunities in the U.S. market, and a reinvigorated BioPharma business. We look forward to continuing to demonstrate operating leverage in 2026 and have high confidence in a material improvement in our financial position."
Full Year 2026 Guidance
Based on information as of today, SOPHiA GENETICS is providing the following FY 2026 guidance:
- Full year revenue between
$92 million $94 million 20% to22% year-over-year growth - Adjusted EBITDA loss between
$29 million $32 million
Executive Transition Plan
SOPHiA GENETICS today announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as President and has been a key executive at the company for five years, will succeed Dr. Jurgi Camblong, co-founder and CEO. Dr. Camblong will transition to Executive Chairman of the Board, subject to election at the company's Annual General Meeting in June 2026.
Throughout 2025, Dr. Camblong has focused on positioning SOPHiA GENETICS for its next phase of growth. As Executive Chairman, he will continue as a full-time executive, concentrating on strategic initiatives, technology innovation, and long-term strategic direction.
"These executive changes reflect the Board's and Dr. Camblong's long-term succession planning," said Dr. Tomer Berkovitz, SOPHiA GENETICS Board Member and Managing Partner at aMoon Fund. "Jurgi has built a remarkable and unique company that has pioneered the application of AI in precision medicine, and we look forward to continuing our work with him, Ross, and the broader leadership team to transform patient care."
Ross Muken joined SOPHiA GENETICS in February 2021, prior to the Company's initial public offering, as Chief Financial Officer (CFO). In March 2023, he expanded his responsibilities to serve as joint CFO and Chief Operating Officer (COO), leading the Company's go-to-market organization, including Clinical Sales, BioPharma Diagnostics Sales, Sales Support, Marketing, Customer Experience, and Operations. In May 2024, Mr. Muken was promoted to company President, overseeing SOPHiA GENETICS' global business operations. In this role, he has played a central role in transforming the commercial organization and sales processes, reaccelerating business growth, and strengthening overall commercial execution.
"The last 15 years have been an incredible journey, realizing our vision to democratize data-driven medicine across more than 70 countries and 800 healthcare institutions. Having worked closely with Ross for five years, I've seen firsthand his exceptional strategic capabilities and operational leadership. I am confident he is the right person to lead the company through its next phase of growth and significantly expand our global impact," said Jurgi Camblong, SOPHiA GENETICS co-Founder.
"Jurgi has built something truly remarkable over the past 15 years, a unique company and technology platform that stands apart in the industry," said Ross Muken. "When I joined in 2021, I immediately recognized this was a category-defining company applying AI and cloud computing at unprecedented scale. Over these five years, working alongside Jurgi has been extraordinary. I've gained deep insights into our customers' needs, our technology's capabilities, and the exceptional talent of our team. I'm deeply honored to succeed Jurgi as CEO and look forward to continuing our partnership as he transitions to Executive Chairman."
Kevin Puylaert, the company's current Managing Director of EMEA, is appointed Chief Sales Officer effective January 2026. Kevin has been with SOPHiA GENETICS for more than 10 years, during which he has held multiple senior leadership roles, and his contributions have been instrumental to the company's growth.
Important Note Regarding Preliminary Unaudited Financial Results
SOPHiA GENETICS has not completed preparation of its financial statements for the fourth quarter or full year of 2025. The estimates presented in this news release for the fourth quarter and year ended December 31, 2025 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete our financial results for the fourth quarter of 2025. SOPHiA GENETICS is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2025, and there can be no assurance that final results for this period will not differ from these estimates. During the course of the preparation of SOPHiA GENETICS' consolidated financial statements and related notes as of and for the year ended December 31, 2025, we may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
SOPHiA GENETICS plans to report its complete fourth quarter and full year 2025 financial results during its first earnings call of 2026 currently scheduled for March 3, 2026.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
Non-IFRS Financial Measures
Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted operating loss (non-IFRS measure) to operating loss (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intangible assets, share-based compensation expenses, non-cash portion of pensions paid in excess of actual contributions, certain transaction costs and litigation expenses that are necessary for such reconciliation.
Forward-Looking Statements
The unaudited financial results for the fourth quarter and full year ended December 31, 2025, in this press release are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment.
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including 2026 guidance and statements regarding our future results of operations and financial position, business strategy, products and technology, partnerships, and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-provides-preliminary-fourth-quarter-and-full-year-2025-financial-results-initiates-2026-guidance-and-announces-executive-transition-plan-302657690.html
SOURCE SOPHiA GENETICS
FAQ
What preliminary Q4 2025 results did SOPH report for revenue and analyses?
What was SOPHiA GENETICS' full‑year 2025 revenue and analysis volume (SOPH)?
What is SOPH's 2026 financial guidance for revenue and adjusted EBITDA?
When does Ross Muken become CEO of SOPH and what happens to the founder?
When will SOPHiA GENETICS report final Q4 and FY 2025 results (SOPH)?
